Incyte Corporation ($INCY) Stock Forecast: Up 5.9% Today

What is Incyte Corporation?

INCY is the ticker symbol for Incyte, a biopharmaceutical company that focuses on the discovery, development, and commercialization of proprietary therapeutics.

Why is Incyte Corporation going up?

INCY stock is up 5.9% on Jul 30, 2025 13:42

• INCY stock experienced a strong bullish movement today.
• The bullish trend can be attributed to Incyte reporting better-than-expected Q2 earnings and revenues, driven by strong sales of Jakafi and Opzelura.
• The company's upward revisions in guidance for Jakafi demand and other oncology products have also contributed to the positive market sentiment.
• Investors are optimistic about the company's performance in the upcoming quarters, especially with the success of their key products and new launches driving revenues.

INCY Price Chart

INCY Technical Analysis

INCY News

INCY's Q2 Earnings & Revenues Beat Estimates on Higher Product Sales

Incyte reports better-than-expected second-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.

https://www.zacks.com/stock/news/2634330/incys-q2-earnings-revenues-beat-estimates-on-higher-product-sales

Incyte Surges Past Expectations With Strong Q2, Boosts Guidance On Jakafi Demand - Incyte ( NASDAQ:INCY )

Incyte Q2 revenue rose 16% to $1.22B, beating estimates; EPS at $1.57 vs. loss of $1.82 YoY Jakafi guidance raised to $3-$3.05 billion for 2025; other oncology products also see upward revisions Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily.

https://www.benzinga.com/markets/earnings/25/07/46693537/incyte-surges-past-expectations-with-strong-q2-boosts-guidance-on-jakafi-demand

Incyte ( INCY ) Surpasses Q2 Earnings and Revenue Estimates

Incyte (INCY) delivered earnings and revenue surprises of +12.95% and +5.56%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

https://www.zacks.com/stock/news/2633127/incyte-incy-surpasses-q2-earnings-and-revenue-estimates

Incyte Gears Up to Report Q2 Earnings: Is a Beat in the Cards?

INCY eyes strong Q2 performance with Jakafi, Opzelura, and new launches like Niktimvo driving revenues.

https://www.zacks.com/stock/news/2613128/incyte-gears-up-to-report-q2-earnings-is-a-beat-in-the-cards

Trending Today

Ethereum ($ETH) Crypto Forecast: Up 5.1% Today

Incyte Corporation Price History

30.06.2025 - INCY Stock was up 5.9%

• INCY stock experienced a strong bullish movement today.
• The bullish trend can be attributed to Incyte reporting better-than-expected Q2 earnings and revenues, driven by strong sales of Jakafi and Opzelura.
• The company's upward revisions in guidance for Jakafi demand and other oncology products have also contributed to the positive market sentiment.
• Investors are optimistic about the company's performance in the upcoming quarters, especially with the success of their key products and new launches driving revenues.

09.11.2024 - INCY Stock was down 5.1%

• Incyte Corporation (INCY) is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The overall market for biopharmaceutical companies can be volatile, with stock movements often influenced by clinical trial results and drug approvals.
• ASSESSMENT:
• Despite Incyte's positive news of meeting primary and secondary goals in a late-stage study for lung cancer treatment, the stock experienced a bearish movement.
• A comparison between Exelixis (EXEL) and Incyte (INCY) might have led investors to reassess the value of INCY, potentially contributing to the bearish trend.
• Investors may have been expecting even more positive results from the study, leading to profit-taking and a temporary dip in the stock price.
• Market sentiment or broader industry trends could have influenced the bearish movement, despite the positive clinical trial outcomes for Incyte.

29.06.2025 - INCY Stock was up 9.1%

• Incyte (INCY) exceeded Q2 earnings and revenue expectations, showcasing a robust performance in the quarter.
• The revenue growth of 16% to $1.22B and EPS of $1.57 compared to a loss of $1.82 YoY contributed to the bullish sentiment.
• Upward revisions in Jakafi guidance to $3-$3.05 billion for 2025, along with positive outlooks on other oncology products, fueled investor optimism.
• The strong performance in Q2, driven by successful products like Jakafi, Opzelura, and new launches, led to increased confidence in Incyte's future prospects, resulting in the bullish market movement.

29.06.2025 - INCY Stock was up 6.0%

• Expectations of a strong Q2 performance with key products like Jakafi, Opzelura, and Niktimvo driving revenues likely contributed to the bullish movement.
• Anticipation of an earnings beat in the upcoming report could have attracted investors to buy INCY stock, leading to the bullish movement.
• Positive sentiment surrounding the company's product portfolio and potential growth prospects might have fueled investor confidence, pushing the stock higher.

19.10.2024 - INCY Stock was down 9.2%

• Incyte Corporation (INCY) stopped enrolling participants in a phase II study of MRGPRX2 in Chronic Spontaneous Urticaria (CSU) due to preclinical toxicology findings, leading to investor apprehension.
• The suspension of enrollment in the study of MRGPRX2 in CSU created a pessimistic atmosphere around Incyte Corporation, contributing to the downward trend in the stock.
• Shareholders responded by selling INCY shares, causing a drop in the stock price as uncertainties about the study's future impact on the company's pipeline surfaced.

19.10.2024 - INCY Stock was down 12.3%

• INCY stock experienced a strong bearish movement following the announcement of a pause in enrollment for a Phase 2 study due to preclinical toxicology findings.
• The decision to halt the study in chronic spontaneous urticaria (CSU) likely raised concerns among investors about the potential impact on future drug development and revenue.
• The negative news surrounding INCY's clinical trial setback contributed to the bearish trend in the stock price as investors reacted to the uncertainty surrounding the company's pipeline and prospects in the biopharmaceutical sector.

26.05.2025 - INCY Stock was up 5.0%

• The FDA approval for the expanded use of Monjuvi in lymphoma is a significant milestone for Incyte, underscoring the company's commitment to developing effective treatments for challenging conditions.
• The approval of Monjuvi in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma creates a new revenue stream for Incyte and strengthens its position in the oncology market.
• The strong bullish movement in INCY stock today is likely influenced by this positive development, as investors react favorably to the company's growth prospects and expanding product portfolio in the competitive biopharmaceutical industry.

11.02.2025 - INCY Stock was down 2.7%

• Positive phase III study results for Opzelura in treating prurigo nodularis may have heightened investor expectations.
• The significant downward movement in INCY's stock suggests the market may have factored in the positive outcomes already, resulting in a sell-off post-announcement.
• Investors seem to be capitalizing on the news by selling for profit, causing a temporary decline in the stock price despite Opzelura's promising efficacy results.

11.02.2025 - INCY Stock was down 5.7%

• INCY is the stock symbol for Incyte, a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics.
• ASSESSMENT:
• The bearish movement in INCY stock today could be due to profit-taking by investors after a strong positive run following the news of Opzelura's superior efficacy in prurigo nodularis studies.
• Despite the positive data from the phase III studies and the encouraging efficacy of their partnered FDA-approved drug, investors may have been expecting even better results, leading to a sell-off.
• The market might be reacting to concerns about the sustainability of the positive outcomes reported, leading to a temporary dip in the stock price.

10.01.2025 - INCY Stock was down 5.0%

• INCY stock had a bearish day attributed to the company's Q4 earnings that fell short of estimates by -6.54%.
• A revenue surprise of 2.63% may have contributed to the negative market sentiment towards the stock.
• Concerns among investors about the company's performance in key metrics for the quarter ended December 2024 are evident.
• The market's response suggests uncertainties about INCY's future, potentially driving the bearish trend.

10.01.2025 - INCY Stock was down 4.6%

• There was unusual options activity indicating a bullish sentiment among deep-pocketed investors, but it did not result in a positive market movement for Incyte today.
• Incyte reported mixed Q4 earnings with revenue surpassing estimates but earnings falling short, which seemed to drive the bearish movement.
• Despite strong sales of key products in Q4 and a positive outlook for 2025 with upcoming launches, the disappointment from the earnings miss contributed to the stock price decline.
• Investors may be exercising caution regarding the future trajectory of Incyte's stock due to the unexpected earnings results and the need for further clarity on the company's financial performance in the coming quarters.

17.02.2025 - INCY Stock was up 5.1%

• Today's surge in Incyte's stock value is a direct result of the successful outcomes from the Phase 3 STOP-HS trials for their latest chronic skin disease medication, Povorcitinib.
• Initial hesitance in the stock price during pre-market trading, attributed to mixed reviews of the trial data, was overshadowed by the drug's effectiveness in patients previously treated with biologics, along with the positive rates of HiSCR50.
• Furthermore, the positive reception towards Incyte's pioneering treatments is reinforced by the promising results of an FDA-approved drug, a collaboration with Eli Lilly, which showed substantial efficacy in young patients grappling with patchy hair loss.
• The continuous progress in Incyte's product pipeline and its commitment to addressing unmet medical needs have instilled confidence in investors regarding the company's potential for future growth, fueling the optimistic upturn in the stock value.